Best Grants for Cancer Nonprofits in Guam

The National Human Genome Research Institute (NHGRI) is launching a Notice of Funding Opportunity (NOFO) aimed at enhancing genomic research through the development and distribution of high-value resources. This initiative encourages collaborative efforts in genomic resource development and the integration of data science in clinical applications. While applications are not currently being accepted, prospective applicants are urged to prepare meaningful collaborations and projects ahead of the formal solicitation.

With a mission to advance cancer research, NIH provides Guam cancer and oncology researchers with funding up to US $1,900,000 for pre-clinical nanotechnology-based diagnostics and therapeutics. Academic or research institutions developing nanoparticle or nano-device cancer interventions that can progress toward NCI translational programs may be strong candidates.

Postdoctoral cancer researchers planning clinical trials in Guam can access funding through the National Institutes of Health’s NCI Pathway to Independence Award (K99/R00). Grants from NIH help oncology and medical training professionals transition from mentored postdoctoral roles to independent, tenure-track or equivalent research positions while building competitive cancer research programs.

The National Cancer Institute's PAIRS program aims to explore innovative cancer therapies by leveraging synthetic vulnerabilities that interact with tumor responses to radiation therapy. This initiative supports the development of targeted drug-radiation combinations, focusing on precision medicine to optimize treatment efficacy while minimizing harm to normal tissues. By consolidating prior funding opportunities, PAIRS encourages research that addresses context-dependent vulnerabilities, enhancing therapeutic strategies and aligning with NIH's scientific goals.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers by funding comprehensive, clinical, and basic cancer research. These grants facilitate the integration of diverse research capabilities, promoting innovative approaches to cancer prevention, diagnosis, and therapy. CCSGs encourage collaboration among researchers and the development of Shared Resources, ultimately enhancing the understanding of cancer and its treatment. This initiative supports the continuous discovery and dissemination of crucial research findings for community benefit.

The National Cancer Institute (NCI) invites research applications focused on early-onset cancers (ages 18-49), aiming to uncover their etiology and biological mechanisms. This funding opportunity supports studies that explore modifiable risk factors, biological responses, and improved identification of at-risk individuals. The initiative seeks to address the concerning rise in these cancers among young adults, facilitating essential prevention and control strategies. Applicants can choose between exploratory or research project formats, with project durations ranging from 2 to 5 years.

The National Cancer Institute's STRIPE program aims to advance cancer therapy by investigating the effects of radionuclide-emitted radiation. This initiative encourages multidisciplinary research to understand how radiation impacts normal tissues and tumor cells, ultimately improving therapeutic outcomes. By consolidating various funding mechanisms, STRIPE seeks to lower entry barriers for researchers, enhance the scientific foundation of radiopharmaceutical therapy, and foster innovative treatment strategies. Projects can be exploratory or research-focused, with flexible timelines for completion.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

This funding opportunity aims to bolster the cancer surveillance workforce through educational initiatives. By enhancing collaborations with cancer partners and developing tools for improved data quality, this program will expand the capacity of registrars. Efforts will focus on recruitment and retention, ultimately ensuring compliance with Public Law 102-515. Strengthening the cancer registrar workforce will lead to timely and accurate cancer data submission, supporting public health objectives.

NIH provides Guam cancer research institutions with US $1,200,000 - US $1,500,000 Cancer Center Support Grants to strengthen NCI-designated Cancer Centers. Funding supports leadership salaries, shared research resources, administration, planning and evaluation, and developmental funds for new recruitments and feasibility studies, helping advance prevention, diagnosis, treatment, and population-based cancer research.

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

The Cancer Health Equity Research Centers (CHERCs) initiative by the American Cancer Society aims to address health disparities by supporting research focused on social determinants affecting cancer care. This program encourages innovative projects that engage communities, enhance access, and improve outcomes across diverse populations. By fostering collaborations and promoting multidisciplinary approaches, CHERCs strive to create equitable cancer prevention and treatment solutions, ensuring that all individuals have fair opportunities for cancer care and survivorship.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

Cancer research institutions and clinical teams in Guam and other eligible U.S. territories can seek funding to integrate imaging and liquid biopsy tumor monitoring during cancer therapy. Focused on advancing cancer/oncology and biomedical imaging, the National Institutes of Health supports R01 projects that optimize these modalities for assessing treatment response and emerging resistance, with awards up to US $2,500,000.

The National Cancer Institute (NCI) invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity allows for biphasic or monophasic applications to support both analytical and clinical validation phases. Successful projects will leverage human specimens to develop assays that enhance cancer treatment and prevention, ensuring multidisciplinary collaboration among scientists and clinicians. This initiative aims to improve cancer management through reliable and clinically validated tools.

Research institutions and universities in Guam working on cancer and biomedical imaging can access funding through the National Institutes of Health to develop molecular imaging methods for studying inflammation in cancer in vivo. Awards up to US $2,500,000 support integrated pre-clinical and clinical imaging research and cross-field collaboration between cancer scientists and imaging experts.

Nonprofit and research organizations developing cancer biomarker assays for detection, diagnosis, prognosis, or treatment response can apply for up to US $275,000 from the National Institutes of Health, including projects in Guam. With a mission to advance cancer research, NIH supports analytical (UH2) and clinical (UH3) validation of high-quality assays using human samples.

Cancer research institutions and clinical laboratories in Guam working on biomarker assays for cancer detection, diagnosis, or treatment response can access funding through the National Institutes of Health. Awards up to US $750,000 support clinical validation of analytically validated molecular, cellular, or imaging markers and harmonization of assay performance across studies and laboratories.

Guam cancer and health-disparities research organizations can access funding through the National Institutes of Health to test clinical trials that expand cancer screening and preventive services. Projects must address barriers and facilitators to screening and follow-up in populations experiencing health disparities, working at multiple levels and in collaboration with community partners and healthcare providers.

Research institutions studying cancer mechanisms after bariatric surgery in Guam and other eligible U.S. territories can apply for National Institutes of Health funding; awards up to US $275,000 support feasibility and exploratory development studies. Projects must investigate how bariatric surgery influences cancer risk, rather than short-term outcomes like weight loss or diabetes.

Cancer research institutions and medical research organizations in Guam can apply for National Institutes of Health support to study how bariatric surgery influences cancer risk, with awards up to US $2,500,000. Focused on cancer and obesity mechanisms, this opportunity supports investigator-initiated R01 projects, including optional clinical trials, through the National Cancer Institute.